Graham Dellaire

Graham Dellaire's expertise spans multiple disciplines including molecular and cellular biology, cancer biology, DNA repair and gene editing. He is also an expert in advanced light and electron microscopy techniques. Dr. Dellaire holds 1 US patent on gene targeting technology and has developed novel assays for correlative light and electron microscopy and for measuring CRISPR/Cas9 gene editing efficiency in human cells. He was a guest editor of the journal Current Gene Therapy, co-editor of the books "The Functional Nucleus" and "Cancer Genomics: from Bench to Personalized Medicine", and is currently an Associate Editor for the journal Chromosome Research.

Formerly a Canadian Institutes of Health Research (CIHR) New Investigator and Co-Chair of the Cancer Research Training Program (CRTP)(2010-2018) at Dalhousie University, Dr. Dellaire is a Dalhousie Distinguished Professor, Senior Scientist of the Beatrice Hunter Cancer Research Institute (BHCRI), Professor and Director of Research in the Department of Pathology at Dalhousie University in Halifax, Canada. Work in his laboratory is focused on increasing the safety and efficiency of CRISPR/Cas9-mediated gene editing, and determining the underlying mechanisms of radiation and chemotherapy resistance in cancer, including dysregulation of DNA repair and alterations in the architecture of the cell nucleus. More recently, Dr. Dellaire has founded the Canadian Environmental Exposures in Cancer (CE2C.ca) Network in 2018. CE2C seeks to facilitate national collaborations to study how environmental carcinogens contribute to cancer development among Canadians, with an initial focus on the health impacts of radon gas and heavy metals like arsenic.